Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the EU / 2025-523033-26-00
Authorised, not yet recruiting Phase II

Boosting osimertinib Blood Brain Barrier penetration in patients with epidermal growth factor receptor mutated non-small cell lung cancer (OSIBBBOOST)

2025-523033-26-00 · tracked via the Priya Life Science EU tracker
Sponsor
Academisch Ziekenhuis Maastricht
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Respiratory Tract Diseases
Decision date
19/03/2026
Enrollment target
14
Sites
Netherlands

Condition studied

Patients with EGFR-mutated metastatic NSCLC, without CNS metastases on brain MRI and without the ABCG2 34G>A SNP, treated with osimertinib as part of regular care are eligible for inclusion. Participants have at least radiologically proven stable disease (SD) or better on regular care osimertinib therapy.

Investigational medicinal product(s)

TAGRISSO 80 mg film-coated tabletsADENURIC 80 mg film-coated tablets

Every trial of Febuxostat and Osimertinib across our registers →

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Osimertinib concentration in CSF and plasma before and after combination with febuxostat

Endpoint detail

Osimertinib concentration in CSF before and after combination with febuxostat, Osimertinib plasma trough concentration before and after addition of febuxostat, AZ5104 and AZ7550 plasma trough concentration before and after combination with febuxostat, AZ5104 and AZ7550 CSF concentration before and after combination with febuxostat, Adverse events according to CTCAE v5.0 criteria, ABCB1 and ABCG2 genotype status, and osimertinib, AZ5104 and AZ7550 CNS concentrations, AEs and osimertinib, AZ5104 and AZ7550 concentrations in blood and CSF

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523033-26-00 on CTIS ↗ ← All trials in the EU